Electrocardiograms (ECGs) All subjects in the Shionogi adult trials of IV peramivir in acute uncomplicated influenza (Studies 0722T0622 and 0815T0631) had 12-lead ECGs performed at Screening, Day 1 (post-dose immediately after completion of infusion), Day 3, and at the completion of study or discontinuation. ECG results were interpreted by a central facility. A total of 29 subjects (2%) had TEAEs of ‘electrocardiogram QT prolonged’ reported; the incidence of these events was comparable across treatment groups: PRV 300 mg 7 (1%), PRV 600 mg 9 (1%), placebo 3 (1%), oseltamivir 10 (3%). Most of these QTc prolongations were minor and two-thirds were noted at the Day 6 visit or beyond, arguing against a causal relationship to study drug. Only two events were considered possibly related to study drug: